Board summary
Key figures
36,866
Registered population
56.3% aged 18–64
26.6%
Aged 65+
ICB 19.0% · England 17.9%
3.6%
Ethnic minority (non-White)
1.2% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 31.9% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
6,874
Hypertension register
+7.67% in 3 yrs · England +5.60%
291
SMI register
7.3% of Cheshire East (LAD)'s
762
COPD register
Reviews +0.36% in 3 yrs
Forecast to 2030
8,288
Hypertension patients, 2030
+1,414 on today
88.2%
QRISK ≥20% on statins, 2030
+9.72pp over 3 yrs
6.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Wide practice spread in telephone contact access.
Easy phone contact ranges from 34.6% at The Kiltearn Medical Ctr. to 100.0% at The Surgery, which may reflect unverified local triage differences.
Secondary-prevention and CKD statin prescribing trails England.
Statin therapy in diabetes with CVD is 76.6% (England 84.4%) and 63.8% in CKD (England 70.3%), which could reflect recall gaps to audit locally.
SMI blood pressure checks exceed national benchmarks.
Annual blood pressure recording on the SMI register reaches 90.4% against 83.4% in England, rising +9.5 pp over 2023 to 2025 (England +4.4 pp).
Population, age and ethnicity
Patients aged 65 and over make up 26.6% of the registered list
Nantwich & Rural PCN cares for 36,866 registered patients across member practices. Patients aged 65+ make up 26.6% (9,806 patients), above Cheshire East (22.6%), the ICB (19.0%) and England (17.9%). Working-age adults aged 18-64 represent 56.3% and under-18s 17.1%, both below comparators. Census usual residents in associated areas are 96.4% White against Cheshire East (94.4%), the ICB (93.0%) and England (81.1%), leaving a 3.6% ethnic minority share; Census resident estimates do not match registered patients. Projected population growth to 2030 is 3.3% using an unverified methodology.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Cheshire East (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Cheshire East LA) | 2,129 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.6% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 59.9% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Cheshire East LA) | 939 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Cheshire East LA) | 14.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Deprivation is low with zero Core20 share recorded across all five member practices
Nantwich & Rural PCN has an average IMD decile of 7.2, compared with 7.1 in Cheshire East, 5.2 in the ICB, and 5.5 in England. Its Core20 share is 0.0%, below Cheshire East (9.2%), the ICB (31.9%), and England (21.0%), representing an estimated zero Core20 patients. Across all five member practices Core20 prevalence is 0.0%, while average IMD deciles span from 6.6 at The Surgery to 7.9 at The Kiltearn Medical Ctr. Inequality work should focus on inclusion health and clinical risk rather than area deprivation.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
291
SMI register
0.80% recorded prevalence
147
Learning disability register
0.40% recorded prevalence
13
Care homes, 643 beds
In the PCN catchment
8.8%
Provide unpaid care
Cheshire East (LAD), Census 2021
Inclusion-health registers record 147 learning disability patients (0.4% against England 0.6%) and 291 severe mental illness patients (0.8% against England 1.0%). Catchment facilities include 13 care homes with 643 beds, though resident registrations and bed occupancy are not captured. Lower register prevalence may reflect local coding or case-finding differences, which local audit could clarify.
Severe mental illness: physical health checks
SMI blood pressure check coverage is 90.4% (Cheshire East 79.0%, ICB 81.3%, England 83.4%) and BMI recording is 87.1% (England 82.1%). Recorded checks exceed comparators, though single indicators do not establish comprehensive physical health review completion.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,874
Hypertension register
+7.67%
Register growth, 3 yrs
Cheshire East (LAD) +6.54% · England +5.60%
+1.23pp
BP control, under 80
≤140/90 · +2.73pp aged 80+
+1,414
More patients by 2030
Forecast 8,288 (21.78%)
Hypertension case-finding and control
The PCN hypertension register holds 6,874 patients, representing 18.8% crude prevalence, compared with 17.3% in Cheshire East, 16.8% across the ICB, and 15.2% in England. The register grew +7.7% from 2023 to 2025, ahead of England (+5.6%). Clinical control is strong: 72.8% of patients are treated to target (England 70.3%), and 70.7% of those aged under 80 achieve blood pressure <= 140/90 mmHg (England 67.8%). However, three-year improvement in under-80 control (+1.8% vs England +3.2%) and recent blood pressure checks (+2.9% vs England +3.6%) trailed national progress. Maintaining proactive recall is important to ensure routine blood pressure monitoring keeps pace with national gains.
Lipids and statins
Although QRISK ≥ 20% lipid therapy grew +18.2% over 2023 to 2025 (England +6.2%), secondary prevention statin treatment trails England in diabetes with CVD (76.6% vs 84.4%) and CKD (63.8% vs 70.3%). Reviewing diabetic and renal registers could help identify patients eligible for secondary-prevention statin therapy.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 83,283 | £1.40 | £1.71 | £1.86 | £116,596 |
| Cardiovascular (all), 2025 | 100,251 | £4.09 | £4.37 | £3.33 | £410,027 |
In 2026, the PCN prescribed 83,283 lipid-regulating items at £1.40 per item, below Cheshire East (£1.72), the ICB (£1.71), and England (£1.86), spending £38,310 less than at England's unit cost. Lower unit cost than comparators does not establish prescribing efficiency, which local review of drug choice would test.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−0.31%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.41%
Asthma prevalence, PCN 3-yr % change
Annual review coverage exceeds national benchmarks for asthma (69.9% vs England 65.7%, Cheshire East 64.5%, ICB 62.3%) across 2,400 registered patients (prevalence 6.9%), and for COPD (80.8% vs England 76.4%, Cheshire East 74.5%, ICB 74.6%) across 762 patients (prevalence 2.1%). However, three-year review growth lags England in both asthma (-0.3% vs +4.4%) and COPD (+0.4% vs +2.8%), leaving an estimated 723 (about 720) asthma patients unreviewed. Prescribing of asthma management items for ages 5-19 is 1,366 per 1,000, below England's 1,488.
Cancer register and children's immunisation
Crude recorded cancer prevalence is 5.6%, compared with 4.9% in Cheshire East, 4.3% across the ICB, and 3.8% in England. Higher recorded prevalence does not establish unmet need or coding differences; local audit would verify diagnostic case-mix.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In 2022, 55.5% of cancers with a known stage (7,482 of 13,490) were diagnosed at stage 1 or 2 across NHS Cheshire and Merseyside ICB, comparable to England (55.3%), but 19.5 percentage points below the 75.0% national ambition by 2028. Staging was known for 72.8% of registered cancers (13,490 of 18,522, above England's 67.0%). Closing the gap to the 75.0% ambition requires about 2,640 additional early-stage diagnoses annually across the ICB. Staging varies by site, from 22.0% in oesophageal cancer to 87.1% in breast cancer, where smaller cohorts warrant caution. These system figures do not measure PCN performance.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Mid Cheshire Hospitals NHS Foundation Trust achieved 71.1% on the 62-day cancer standard (13.9 percentage points below the 85.0% standard), close to England (71.2%) but behind Countess of Chester Hospital NHS Foundation Trust (83.3%) and the ICB (76.2%), while exceeding University Hospitals of North Midlands NHS Trust (68.8%). Mid Cheshire reached 80.0% on the 28-day faster diagnosis standard (standard 75.0%; England 79.3%). Diagnostic 6-week waits were 5.2% for MRI and 1.1% for CT (England 21.4% and 9.9%). Provider waiting times reflect acute pressures rather than PCN performance.
| Pathways within standard (%) | Mid Cheshire | of North Midlands | Countess of Chester | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 79.95 | 80.65 | 87.37 | 77.25 | 79.32 |
| 31-day treatment (96%) | 86.21 | 93.85 | 93.48 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 71.12 | 68.84 | 83.28 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Mid Cheshire | of North Midlands | Countess of Chester | England |
|---|---|---|---|---|
| MRI | 5.15 | 36.13 | 11.26 | 21.40 |
| CT | 1.09 | 2.86 | 4.18 | 9.92 |
| Echocardiography | 5.51 | 45.39 | 31.44 | 28.48 |
| Colonoscopy | 30.34 | 46.53 | 26.44 | 30.83 |
| Gastroscopy | 31.89 | 15.49 | 27.52 | 29.02 |
| All 15 DM01 tests | 12.72 | 22.94 | 20.16 | 23.14 |
| Community services activity | Cheshire East residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 72,825 | 541,280 |
| Referrals | 18,280 | 97,150 |
| Patients with a contact | 21,910 | 146,240 |
Community services (residents of Cheshire East), Jun 2026 (provisional). In June 2026, provisional community services data showed that adults aged 65 and over accounted for 60.8% of all community contacts among Cheshire East residents (44,295 of 72,825 contacts). This borough-level activity reflects substantial older-age service demand across community pathways, consistent with Nantwich & Rural PCN's older demographic profile, though community activity is not captured at PCN level.
Practice variation and patient experience
GP phone access spans 65.4 percentage points across the five member practices
In 2025/26, overall QOF achievement ranged from 95.5% at The Surgery to 98.5% at Nantwich Health Centre (England 92.5%). Vaccination domain achievement showed a 36.0 pp spread across member practices. Domain achievement was 60.5% at The Surgery and 96.5% at Tudor Surgery (England 55.2%), while all-domain personalised care adjustments reached 12.5% at Tudor Surgery versus 4.5% at The Surgery.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| The Surgery | 114 | 0.0 | 100.0% | 80.1% | 99.3% |
| Audlem Medical | 121 | 0.0 | 79.3% | 75.6% | 88.5% |
| Nantwich | 105 | 0.0 | 59.2% | 82.9% | 85.1% |
| Tudor Surgery | 86 | 0.0 | 69.6% | 56.7% | 80.0% |
| Kiltearn Medical | 111 | 0.0 | 34.6% | 68.8% | 66.2% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fifteen of 25 measures trail national three-year trends despite strong baseline review coverage
From 2023 to 2025, 15 of 25 measures trailed England's three-year change. Annual review trajectories were negative in heart failure (-4.6% vs England +8.7%) and asthma (-0.3% vs England +4.4%), while COPD review growth reached +0.4% (England +2.8%). Current PCN coverage still exceeds England in all three (heart failure 81.0% vs 78.5%; COPD 80.8% vs 76.4%; asthma 69.9% vs 65.7%). Strengths include QRISK ≥ 20% lipid therapy (+18.2% vs England +6.2%) and mental health blood pressure checks (+9.5 pp vs England +4.4 pp). Trailing review trends could reflect recall capacity pressures to verify locally.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Asthma reviews
Learning disability register
COPD reviews
Stroke register
QRISK statin treatment
BP check (SMI)
Diabetes statin (no CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Cheshire East (LAD) | Asset | PCN | Cheshire East (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 13 (643 beds) | n/a | Schools (catchment) | 46 | n/a |
| Children's centres | 1 | 14 | Places of worship | 48 | 272 |
| Libraries | 1 | 16 | Day centres (VCS) | n/a | 1 |
| Children and young people (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 9 | 41 | Primary academies | 12 | 78 |
| Special schools | n/a | 5 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Audit practice telephone and triage access
In the 2026 GP Patient Survey, ease of phone contact spans 65.4 pp, from 34.6% at The Kiltearn Medical Ctr. to 100.0% at The Surgery (England 56.9%). For discussion, practices could review call demand, telephony routing and triage workflows at lowest-scoring sites and share effective access models. Moderate effort to run.
Evidence base: patient-reported access and experience is the demand-side signal on primary-care capacity and access model; practices with sustained poor experience are the ones to prioritise for access-model support.
Policy anchor: 10 Year Health Plan, shift from hospital to community (Neighbourhood Health Service).
Option 2
Standardise annual asthma review recall
Asthma review coverage is 69.9% of 2,400 patients (England 65.7%), but 2023 to 2025 change was -0.3% vs England +4.4%, leaving 723 (about 720) unreviewed. For discussion, member practices could standardise annual asthma recall templates, align inhaler checks with reviews, and offer flexible clinic slots. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Validate learning disability register coding
Learning disability prevalence is 0.4% (147 of 36,866 patients) vs Cheshire East 0.5% and England 0.6% (+22 to +70 benchmark gap range), growing +2.2% vs England +5.4%. For discussion, practices could search clinical systems for unlinked diagnostic codes and cross-check lists with local authority social-care records. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Frail older adult capacity review (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Inclusion health inequality pivot (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Hypertension recall audit (p5) | Hypertension patients with a recent blood pressure reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Cancer pathway safety-netting audit (p7) | Cancers diagnosed at stage 1 or 2 (All cancer sites) | — | ICB |
| Telephone access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Audit practice telephone and triage access (p12) | GPPS easy to contact the practice by phone · GPPS survey response rate | 10YHP, hospital to community | Practice |
| Option 2 · Standardise annual asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · Validate learning disability register coding (p12) | Learning disability register · Learning disability: QOF prevalence · Registered population | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
